The Smart Solution for
Preclinical Development


Our oncology CRO services are performed by trained scientists committed to accelerating new cancer immunotherapies, vaccines, and T-cell therapies. We are adept in developing targeted therapies that will improve outcomes for patients.

Let Noble Life Sciences’ unparalleled expertise and state-of-the-art facilities be your trusted partner for all of your preclinical biodistribution and shedding studies. We have worked with xx organizations to bring xx new therapies to market.

Oncology Capabilities

We ensure the creation of unique models and comprehensive services


  • Cell & Gene Therapy
  • Immuno-Oncology
  • Vaccines
  • Small Molecules
Cancer Models

Mouse Models

  • Cell line-derived xenograft models
  • Syngeneic models
  • Humanized mouse models
  • Patient-derived xenograft models
  • Graft vs Host disease (GvHD) models

We ensure creation of unique models and comprehensive services

  • Expansion & activation of CAR-T cells
  • Flexibility to build out T-cell production capabilities
  • Flow cytometry-based assays to support immuno-oncology drug development
  • IVIS live animal imaging
  • Cytotoxicity & Immunotoxicity assays
  • PK/PD & efficacy studies
  • Flow and PCR based biodistribution assays

In Vivo Cancer Models

Noble Scientists have deep experience designing and implementing a variety of animal models to characterize oncology drug candidates for efficacy, pharmacodynamics, pharmacokinetics, toxicity and bioavailability. Models include:



  • Humanized rodent models for immune-oncological studies
  • Syngeneic tumor models for immuno-oncological drug studies
  • Oncolytic virus mediated cancer therapy model

Patient Derived Xenograft (PDX)

  • Ectopic & Orthotopic

Cell Line Derived Xenograft (CDX)

  • Immunocompromised rodent models for CAR – T treatment studies
  • Xenograft Models
  • Breast Adenocarcinoma Model
  • Orthotopic & Ectopic Models
    • Breast tumor in mammary fat pad
    • Liver tumor
    • Glioma or other kinds of Brain tumors
  • Metastatic Models
  • Leukemia Models
  • Cell Therapy Models

The Industry Standard

Noble’s OncoDiversity Cell Line Panel will hit the target

Noble will screen your drug candidates using our OncoDiversity Cell Line Panel, a diverse collection of cell lines spanning multiple cancer indications.

Results from the cell line panel screen can be matched to the genetic background in the cancer cell lines to determine a molecular biomarker profile correlating with the activity of your drug candidate.

Noble’s biobank resource containing DNA and protein from each cell line is then used to confirm the drug: biomarker correlations that were discovered in the cell panel screen.

Validation of the drug and biomarker response in vivo can be carried out in cell models shown to be sensitive to your drug.

These studies provide an understanding of the expression status of the target and molecular pathway in the selected model; determination of the active plasma concentrations of the drug; modulation of the downstream pathway in which the target functions; and assessment of the therapeutic index.

By examining the response of a broad spectrum of validated DNA and protein-based biomarkers to therapeutics, we deliver data that enables more confident decisions.

Imaging capabilities

Live animal imaging with the Perkin Elmer IVIS system using bioluminescent or fluorescent reporters

Scientific Advisor Team

Our oncology team is committed to fight The Fight

by advancing your preclinical research.

Stephen K. Horrigan, Ph.D.

Stephen K. Horrigan, Ph.D.

Chief Scientific Officer

Pang-Kuo Lo, Ph.D. MSc

Pang-Kuo Lo, Ph.D. MSc

Team Lead, Assay Development

Arundhati Ghosh, Ph.D., MSc

Arundhati Ghosh, Ph.D., MSc

Study Director

Yongping Chen, M.D., Ph.D.

Yongping Chen, M.D., Ph.D.

Senior Study Director

We can help to lead the global fight against cancer

Resources & White Papers


Mouse Peritonitis/Sepsis Model of MRSA Infection

Mouse Peritonitis/Sepsis Model of MRSA Infection

Noble Life Sciences, in collaboration with ImQuest Biosciences, has optimized the peritonitis/sepsis mouse model to screen for new antibacterial agents against methicillin-resistant Staphylococcus aureus (MRSA). The model’s popularity derives from its ease of use with small and expensive animals, short-duration experiments with reproducible infections, and simple end-points.

read more